$NRSN

3 stories mentioning NRSNUpdated 31d ago

Every FINWIRES story that references NRSN, newest first.

NeuroSense Says Phase 2b Trial of PrimeC in Amyotrophic Lateral Sclerosis Meets Primary Endpoint

NeuroSense Therapeutics (NRSN) said Monday its phase 2b trial of its lead drug candidate PrimeC in amyotrophic lateral sclerosis met its primary efficacy endpoint, showing a "statistically significant" decrease in TDP-43 levels compared with placebo at day 180.The decrease in TDP-43, recognized as the pathological signature of ALS, gives biological evidence that PrimeC is engaging a core disease mechanism, the company said, adding that the reduction was sustained through 18 months.NeuroSense said that after obtaining US Food and Drug Administration clearance to start a global phase 3 trial, it is advancing trial preparations and engaging with regulators in several jurisdictions, including Canada.PrimeC is an oral formulation composed of FDA-approved ciprofloxacin and celecoxib.NeuroSense shares were up more than 8% in Monday trading.Price: $0.82, Change: $+0.06, Percent Change: +8.27%

$NRSN

Sectors51d ago

Sector Update: Healthcare Stocks Rise Tuesday Afternoon

Healthcare stocks were higher Tuesday afternoon, with the NYSE Healthcare Index rising 1.1% and the State Street Health Care Select Sector SPDR ETF (XLV) increasing 0.8%.The iShares Biotechnology ETF (IBB) rose 0.2%.In corporate news, GSK (GSK) said it signed a definitive agreement Tuesday to acquire Nuvalent (NUVL) for $10.6 billion in cash. GSK shares rose 0.9%, and Nuvalent surged 39%.Eli Lilly (LLY) entered into a collaboration and licensing agreement worth over $1 billion with Swedish pharmaceutical company AlzeCure Pharma for global rights to its investigative candidate for Alzheimer's disease. Lilly shares were down 0.5%.NeuroSense Therapeutics (NRSN) shares added 1% after it said Tuesday that it has been issued a patent by the Japan Patent Office for PrimeC, its lead drug candidate to treat amyotrophic lateral sclerosis.

$GSK$LLY$NRSN$NUVL

Wire93d ago

NeuroSense Therapeutics Prices $600,000 Private Placement of Shares

NeuroSense Therapeutics (NRSN) said Tuesday it will sell 750,000 shares at $0.80 apiece in a private placement for gross proceeds of $600,000.The private placement, expected to close next week, was led by Chief Executive Alon Ben-Noon, Chief Financial Officer Or Eisenberg, and an existing shareholder, each committing $200,000, the company said.NeuroSense said it plans to use the proceeds from the offering for general corporate purposes as it approaches clinical and regulatory milestones.Price: $0.80, Change: $+0.05, Percent Change: +6.60%

$NRSN

Track with the FINWIRES app suite

FolioX

Track NRSN in your portfolio

WheelAI

Analyze NRSN options with the wheel strategy

StockInsider

See market sentiment on NRSN